Key Takeaway: Entera has appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer, bringing 30 years of experience in global pharmaceutical research and clinical development. His previous roles include positions at Sumitomo Pharma, Takeda, and Novartis. This appointment is expected to bolster Entera's clinical execution team and support the planned initiation of the EB613 Phase 3 trial.
Market Sentiment Analysis
POSITIVE FACTORS
Appointment of a highly experienced CMO.
Strengthens Entera's clinical execution team.
Enhances late-stage development capabilities.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+292%
120-day peak, hindsight
Typical move
5.5%
average across 5 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
EBP05
Phase 2 · Osteoporosis
Full Press Release Details
Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera’s clinical execution team and late-stage development capabilities ahead of planned EB613
Frequently Asked Questions
Who is the new Chief Medical Officer of Entera?
Dr. Riccardo Paolo Camisasca has been appointed as the new CMO.
What is Dr. Camisasca's experience in the pharmaceutical industry?
He has 30 years of experience in global pharmaceutical research and clinical development.
What companies did Dr. Camisasca work for before Entera?
He held roles at Sumitomo Pharma, Takeda, and Novartis.
What is the significance of Dr. Camisasca's appointment?
His appointment strengthens Entera's clinical execution team and late-stage development capabilities.